Phase i and pharmacokinetic study of nab-paclitaxel, nanoparticle albumin-bound paclitaxel, administered weekly to Japanese patients with solid tumors and metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 2, 2012, Pages 457-465

  Ando, Masashi ^a   Yonemori, Kan ^a   Katsumata, Noriyuki ^a   Shimizu, Chikako ^a   Hirata, Taizo ^a   Yamamoto, Harukaze ^a   Hashimoto, Kenji ^a   Yunokawa, Mayu ^a   Tamura, Kenji ^a   Fujiwara, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

Albumin bound paclitaxel; Ocular toxicity; Phase I study; Weekly administration

Indexed keywords

AMINOTRANSFERASE; DOCETAXEL; PACLITAXEL;

ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; BLOOD TOXICITY; BLOOD TRANSFUSION; BREAST CANCER; BREAST SURGERY; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL ARTICLE; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; EDEMA; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; JAPANESE; KERATOPATHY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVARY CANCER; PERIPHERAL EDEMA; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; RECOMMENDED DRUG DOSE; RETINA MACULA HOLE; SENSORY NEUROPATHY; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; URETHRA CANCER; VOMITING;

ADULT; AGED; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EXANTHEMA; FEMALE; HUMANS; JAPAN; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NANOPARTICLES; NAUSEA; NEOPLASM METASTASIS; NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME;

EID: 84856739715     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1726-5     Document Type: Article

References (21)

1. EK Rowinsky RC Donehower 1995 Paclitaxel (taxol) N Engl J Med 332 1004 1014 7885406 10.1056/NEJM199504133321507 1:STN:280:DyaK2M7ptFKisg%3D%3D
2. H Gelderblom J Verweij K Nooter A Sparreboom 2001 Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur J Cancer 37 1590 1598 11527683 10.1016/S0959-8049(01)00171-X 1:CAS:528: DC%2BD3MXmt1Oqtb0%3D (Pubitemid 32778603)
3. RB Weiss RC Donehower PH Wiernik, et al. 1990 Hypersensitivity reactions from taxol J Clin Oncol 8 1263 1268 1972736 1:STN:280:DyaK3c3ptlyitw%3D%3D (Pubitemid 20195638)
4. E Miele GP Spinelli E Miele, et al. 2009 Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer Int J Nanomedicine 4 99 105 19516888 1:CAS:528:DC%2BD1MXhsVKjsrrM
5. N Desai V Trieu Z Yao, et al. 2006 Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel Clin Cancer Res 12 1317 1324 16489089 10.1158/1078-0432.CCR-05-1634 1:CAS:528:DC%2BD28XhsFaltbY%3D (Pubitemid 43342524)
6. WJ Gradishar S Tjulandin N Davidson, et al. 2005 Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in woman with breast cancer J Clin Oncol 23 7794 7803 16172456 10.1200/JCO.2005.04.937 1:CAS:528:DC%2BD2MXht1Cqs7nK (Pubitemid 46657376)
7. AD Seidman D Berry C Cirrincione, et al. 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642 1649 18375893 10.1200/JCO.2007.11.6699 1:CAS:528:DC%2BD1cXltlWhsr0%3D
8. JA Sparano M Wang S Martino, et al. 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 18420499 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D (Pubitemid 351549913)
9. DW Nyman KJ Campbell E Hersh, et al. 2005 Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies J Clin Oncol 23 7785 7793 16258082 10.1200/JCO.2004.00.6148 1:CAS:528:DC%2BD2MXht1Cqs7nI (Pubitemid 46657375)
10. WJ Gradishar D Krasnojon S Cheporov, et al. 2009 Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer J Clin Oncol 27 3611 3619 19470941 10.1200/JCO.2008.18.5397 1:CAS:528:DC%2BD1MXhtVOnu7nE
11. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D (Pubitemid 30099779)
12. K Yamada N Yamamoto Y Yamada, et al. 2010 Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors Jpn J Clin Oncol 40 404 411 20133335 10.1093/jjco/hyp192
13. SV Smith MS Benz DM Brown 2008 Cystoid macular edema secondary to albumin-bound paclitaxel therapy Arch Ophthalmol 126 1605 1606 19001234 10.1001/archopht.126.11.1605
14. CG Murphy JB Walsh CA Hudis, et al. 2010 Cystoid macular edema secondary to nab-paclitaxel therapy J Clin Oncol 28 e684 e687 20805460 10.1200/JCO.2010.30.3750
15. WE Smiddy HW Flynn Jr 2004 Pathogenesis of macular holes and therapeutic implications Am J Ophthalmol 137 525 537 15013877 10.1016/j.ajo.2003.12.011 1:CAS:528:DC%2BD2cXhvVygsbs%3D (Pubitemid 38328645)
16. NK Ibrahim N Deasi S Legha, et al. 2002 Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin Cancer Res 8 1038 1044 12006516 1:CAS:528:DC%2BD38XksVSqurg%3D (Pubitemid 34517637)
17. NK Ibrahim B Samuels R Page, et al. 2005 Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer J Clin Oncol 23 6019 6026 16135470 10.1200/JCO.2005.11.013 1:CAS:528: DC%2BD2MXhtVKgtb3I
18. 2 J Clin Oncol 12 1741 1742 7913722 1:STN:280:DyaK2czhsFCjsA%3D%3D (Pubitemid 24245015)
19. A Sparreboom CD Scripture V Trieu, et al. 2005 Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11 4136 4143 15930349 10.1158/1078-0432.CCR-04-2291 1:CAS:528: DC%2BD2MXks1Gks7g%3D (Pubitemid 40791578)
20. ER Gardner WL Dahut CD Scripture, et al. 2008 Randomized crossover Pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel Clin Cancer Res 14 4200 4205 18594000 10.1158/1078-0432.CCR-07-4592 1:CAS:528: DC%2BD1cXnvFyksrs%3D
21. MT Huizing AC Keung H Rosing, et al. 1993 Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients J Clin Oncol 11 2127 2135 7901342 1:STN:280: DyaK2c%2FksFyitA%3D%3D (Pubitemid 23332248)